{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Peritoneum&page=6", "query": { "condition": "Malignant Neoplasm of Peritoneum", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 655, "total_pages": 66, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Peritoneum&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Peritoneum&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T22:17:49.825Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00910000", "title": "Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2009-06", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2018-09-10", "last_synced_at": "2026-10-10T22:17:49.825Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00910000" }, { "nct_id": "NCT05920798", "title": "Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fallopian Tube Carcinosarcoma", "Primary Peritoneal Carcinosarcoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Fallopian Tube Clear Cell Adenocarcinoma", "Recurrent Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Fallopian Tube High Grade Serous Adenocarcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Carcinosarcoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma", "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Carcinosarcoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pheresis", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 38, "start_date": "2023-09-28", "completion_date": "2030-10-28", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-10T22:17:49.825Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05920798" }, { "nct_id": "NCT00692900", "title": "Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "intravenous docetaxel with intraperitoneal oxaliplatin", "type": "DRUG" }, { "name": "intravenous oxaliplatin with intraperitoneal docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2008-12", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-10-10T22:17:49.825Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00692900" }, { "nct_id": "NCT00005836", "title": "Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": null, "start_date": "2000-02", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-10-10T22:17:49.825Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005836" }, { "nct_id": "NCT01649336", "title": "A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "MEK162, MEK inhibitor; oral", "type": "DRUG" }, { "name": "Paclitaxel, mitotic inhibitor; intravenous", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 36, "start_date": "2012-07", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2020-09-14", "last_synced_at": "2026-10-10T22:17:49.825Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Lafayette, Indiana • New York, New York + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01649336" }, { "nct_id": "NCT02399371", "title": "Pembrolizumab in Treating Patients With Malignant Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biphasic Mesothelioma", "Epithelioid Mesothelioma", "Peritoneal Malignant Mesothelioma", "Pleural Biphasic Mesothelioma", "Pleural Epithelioid Mesothelioma", "Pleural Malignant Mesothelioma", "Pleural Sarcomatoid Mesothelioma", "Recurrent Peritoneal Malignant Mesothelioma", "Recurrent Pleural Malignant Mesothelioma", "Sarcomatoid Mesothelioma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-03-31", "completion_date": "2026-03-20", "has_results": true, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-10T22:17:49.825Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02399371" }, { "nct_id": "NCT07322094", "title": "CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "FIGO Stage III and IV Ovarian Cancer", "Fallopian Tube Cancers", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "TORL-1-23 and paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "TORL-1-23 and carboplatin", "type": "COMBINATION_PRODUCT" }, { "name": "TORL-1-23, paclitaxel, and carboplatin", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "TORL Biotherapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 60, "start_date": "2025-12-10", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-10T22:17:49.825Z", "location_count": 7, "location_summary": "Fullerton, California • Irvine, California • Los Angeles, California + 3 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07322094" }, { "nct_id": "NCT00053365", "title": "Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Peritoneal Cavity Cancer", "Recurrent Ovarian Epithelial Cancer" ], "interventions": [ { "name": "irofulven", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "FEMALE", "summary": "18 Years to 85 Years · Female only" }, "enrollment_count": 61, "start_date": "2003-06", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2019-07-24", "last_synced_at": "2026-10-10T22:17:49.825Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053365" }, { "nct_id": "NCT00005645", "title": "ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Metastatic Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "ILX-295501", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 0, "start_date": "1999-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2018-09-18", "last_synced_at": "2026-10-10T22:17:49.825Z", "location_count": 8, "location_summary": "Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Billings", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005645" }, { "nct_id": "NCT00091195", "title": "Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Peritoneal Cavity Cancer", "Recurrent Ovarian Epithelial Cancer" ], "interventions": [ { "name": "romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 51, "start_date": "2004-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-19", "last_synced_at": "2026-10-10T22:17:49.825Z", "location_count": 2, "location_summary": "High Point, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "High Point", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091195" } ] }